IP Library Granted Patent US 7,169,916
Granted Patent B2
US 7,169,916 · App. 10/403,692 · Granted Jan 30, 2007

Chloral-free DCA in oligonucleotide synthesis

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,169,916
App. No.
10/403,692
Granted
Jan 30, 2007
Kind
B2
Abstract

A process of manufacturing oligonucleotides includes a 5′-deblocking step in which the 5-blocking group is removed with dichloroacetic acid that is essentially free of chloral. The process is useful for making oligonucleotides that are substantially free of chloral adducts.

Claims (8)

1. A process comprising contacting an oligonucleotide bearing a dimethoxytriphenylmethyl blocking group with dichloroacetic acid having less than about 0.03 weight percent chloral hydrate.

2. The process of claim 1 , wherein said dichloroacetic acid is present in the form of a dichloroacetic acid-containing solution.

3. An oligonucleotide prepared by the process of claim 1 .

4. The oligonucleotide of claim 3 , wherein the oligonucleotide adducts of chloral are excluded to the extent that their concentration is below the limit of detection for oligonucleotide adducts of chloral.

5. The process of claim 1 , wherein the trityl blocking group is 4,4′-dimethoxytriphenylmethyl.

6. The process of claim 1 , wherein the oligonucleotide is bound to a solid support.

7. The process of claim 2 , wherein the dichloroacetic acid-containing solution further comprises an arene solvent.

8. The process of claim 7 , wherein the arene solvent is toluene.

Assignments (1)
CHANGE OF NAME Recorded Jul 26, 2017
From: ISIS PHARMACEUTICALS, INC.
To: IONIS PHARMACEUTICALS, INC.
Reel/Frame 043341/0557 →